A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand

Lijoy Varghese,Louise Talbot,Andrea Govender,Xu-Hao Zhang,Bruce A. Mungall

A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand

2018

Lijoy Varghese
Louise Talbot
Andrea Govender
Xu-Hao Zhang
Bruce A. Mungall

Abstract Objectives Invasive pneumococcal disease (IPD), pneumonia and acute otitis media (AOM) still represent a significant medical burden in children

Keywords:

Haemophilus influenzae
Cost-effectiveness analysis
Acute otitis media
Vaccination
Physical therapy
Pneumococcal conjugate vaccine
Pediatrics
Medicine
Conjugate vaccine
non typeable
pneumococcal disease
mass vaccination
Virology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations